Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Correspondent™ provides on-site daily coverage of key sessions at particular scientific meetings. Conference Correspondent™ takes healthcare providers to meetings they cannot attend live, and your sponsorship helps create awareness for your brand or therapeutic area.
View All Conference Highlights
NSCLC IO 2022 Midyear Review
Circulating Tumor DNA–Guided Therapy of Advanced NSCLC with Immune Checkpoint Inhibitor–Based Regimens
NSCLC IO 2022 - Midyear Review
– June 16, 2022
NSCLC IO 2022 - Midyear Review
Lung Cancer Treatment Selection Based on a Multiplexed Proteomic Assay
NSCLC IO 2022 - Midyear Review
– June 16, 2022
NSCLC IO 2022 - Midyear Review
Machine Learning–Based Integration of Radiology, Pathology, and Genomics to Predict Response to PD-1 Inhibition in Patients with NSCLC
NSCLC IO 2022 - Midyear Review
– June 16, 2022
NSCLC IO 2022 - Midyear Review
Investigation of Acquired Resistance Biomarkers to Anti–PD-(L)1 Therapy in Patients with Advanced NSCLC
NSCLC IO 2022 - Midyear Review
– June 16, 2022
NSCLC IO 2022 - Midyear Review
Time-Dependent Efficacy of Nivolumab in Patients with Advanced NSCLC
NSCLC IO 2022 - Midyear Review
– June 16, 2022
NSCLC IO 2022 - Midyear Review
VIEW FULL COVERAGE
ASCO 2022 – Wrap Up
DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer
ASCO 2022 – Wrap-Up
– June 14, 2022
American Society of Clinical Oncology (ASCO)
TROPiCS-02 Primary Results: Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Advanced Breast Cancer
ASCO 2022 – Wrap-Up
– June 14, 2022
American Society of Clinical Oncology (ASCO)
Ribociclib Efficacious in Patients with Unresectable or HR-Positive/HER2-Negative Metastatic Breast Cancer Receiving Fulvestrant or Exemestane After Not Responding to Prior Treatments
ASCO 2022 – Wrap-Up
– June 14, 2022
American Society of Clinical Oncology (ASCO)
Event-Free Survival by Residual Cancer Burden After Neoadjuvant Chemotherapy + Pembrolizumab for Early TNBC: KEYNOTE-522 Data
ASCO 2022 – Wrap-Up
– June 14, 2022
American Society of Clinical Oncology (ASCO)
Revised Overall Survival and Progression-Free Survival Data from the FAKTION Study: Capivasertib + Fulvestrant in Metastatic, ER-Positive Breast Cancer
ASCO 2022 – Wrap-Up
– June 14, 2022
American Society of Clinical Oncology (ASCO)
VIEW FULL COVERAGE
Dual IO 2021 Year in Review
Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma
Dual IO 2021 - Year in Review
– March 7, 2022
Dual IO 2021 - Year in Review
Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)
Dual IO 2021 - Year in Review
– March 7, 2022
Dual IO 2021 - Year in Review
Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
By Sanjiv S. Agarwala, MD
Dual IO 2021 - Year in Review
– March 7, 2022
Dual IO 2021 - Year in Review
Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047
Dual IO 2021 - Year in Review
– March 7, 2022
Dual IO 2021 - Year in Review
Nivolumab plus Ipilimumab as First-Line Therapy in Patients with Advanced Melanoma: 6.5-Year Update from CheckMate-067
Dual IO 2021 - Year in Review
– March 7, 2022
Dual IO 2021 - Year in Review
VIEW FULL COVERAGE
SABCS 2021 - Wrap-Up
Finding Your Strength Through Knowledge: Proceedings from the San Antonio Breast Cancer Symposium
SABCS 2021 – Wrap-Up
– December 10, 2021
San Antonio Breast Cancer Symposium (SABCS)
Updated Outcomes of Tucatinib versus Placebo Added to Trastuzumab and Capecitabine (HER2CLIMB) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer with Brain Metastases
SABCS 2021 – Wrap-Up
– December 10, 2021
San Antonio Breast Cancer Symposium (SABCS)
Finding Your Strength Through Knowledge
By Sharon Gentry, RN, MSN, AOCN, CBCN, HON-ONN-CG
SABCS 2021 – Wrap-Up
– December 10, 2021
San Antonio Breast Cancer Symposium (SABCS)
Results from the I-SPY 2 Trial of Tucatinib plus Paclitaxel + Pertuzumab + Trastuzumab Followed by Doxorubicin/Cyclophosphamide in High-Risk HER2-Positive Stage II/III Breast Cancer
SABCS 2021 – Wrap-Up
– December 10, 2021
San Antonio Breast Cancer Symposium (SABCS)
A Review of the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Patients with HER2-Positive Breast Cancer with or without Brain Metastases
SABCS 2021 – Wrap-Up
– December 10, 2021
San Antonio Breast Cancer Symposium (SABCS)
VIEW FULL COVERAGE
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us